Skip to main content
OpenTrials
Completed

NCT Number: NCT01901159

A Study of RO4995819 to Assess Bioavailability and Safety in Healthy Volunteers

This randomized, open-label, cross-over study will assess the bioavailability and safety of RO4995819 in healthy volunteers. Volunteers will receive two different formulations (tablet and capsule) of the study drug under fed and fasting conditions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Rennes, 35042, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy non-smoking male and female volunteers, 18 to 65 years of age, inclusive.
  • A body mass index (BMI) between 18 to 30 kg/m2, inclusive.
  • Able to participate and willing to give written informed consent and to comply with the study restrictions.
  • Willing not to participate in any other clinical trial with an investigational drug or device for at least 3 months following the follow up visit.
  • Male volunteers and their partners of childbearing potential must use two adequate methods of contraception. Female volunteers who are not either surgically sterile or postmenopausal must commit to use two adequate methods of contraception throughout the study and until at least 5 months after last dosing.

Exclusion criteria

  • History of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological, hematological or allergic disease, metabolic disorder or cancer
  • Significant past or present disorders of the central nervous system, psychiatric disorders, behavioral disturbances
  • Diseases or medical conditions that are capable of altering the absorption, metabolism or elimination of drugs
  • Any condition or disease detected during the medical interview / physical examination that would render the volunteer unsuitable for the study, place the volunteer at undue risk or interfere with the ability of the volunteer to complete the study in the opinion of the Investigator
  • Clinically significant abnormalities in laboratory test results
  • Confirmed resting pulse rate greater than 90 or less than 40 beats per minute (bpm) at screening
  • Confirmed systolic blood pressure (SBP) greater than 140 or less than 90 mm Hg, and diastolic blood pressure (DBP) greater than 90 or less than 50 mm Hg at screening
  • Any major illness within the 4 weeks prior to dosing or any acute disease state within 7 days of study start
  • Any confirmed allergic reaction against any drug or multiple allergies
  • Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse
  • Infection with hepatitis B, hepatitis C virus, or HIV 1 and HIV 2

Treatment and study plan

RO4995819

Drug

Oral doses of RO4995819 (tablet)

Primary outcomes

  1. Bioavailability: Plasma concentration of RO4995819

    Time frame: Approximately 3 months

Secondary outcomes

  1. Safety: incidence of adverse events

    Time frame: Approximately 3 months

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Jul 17, 2013
Registry last updated
Nov 2, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.